These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Informed consent in the context of pharmacogenomic research: ethical considerations. Howard HC; Joly Y; Avard D; Laplante N; Phillips M; Tardif JC Pharmacogenomics J; 2011 Jun; 11(3):155-61. PubMed ID: 21445091 [TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report. Corrigan OP J Med Ethics; 2005 Mar; 31(3):144-8. PubMed ID: 15738433 [TBL] [Abstract][Full Text] [Related]
24. Finding a liability-free space in which personalized medicine can bloom. Evans BJ Clin Pharmacol Ther; 2007 Oct; 82(4):461-5. PubMed ID: 17713468 [TBL] [Abstract][Full Text] [Related]
25. Pharmacogenomic data sample collection and storage: ethical issues and policy approaches. Joly Y; Knoppers BM Pharmacogenomics; 2006 Mar; 7(2):219-26. PubMed ID: 16515401 [TBL] [Abstract][Full Text] [Related]
26. Racializing drug design: implications of pharmacogenomics for health disparities. Lee SS Am J Public Health; 2005 Dec; 95(12):2133-8. PubMed ID: 16257939 [TBL] [Abstract][Full Text] [Related]
27. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. van Delden J; Bolt I; Kalis A; Derijks J; Leufkens H Bioethics; 2004 Aug; 18(4):303-21. PubMed ID: 15449404 [TBL] [Abstract][Full Text] [Related]
28. Privacy issues in personalized medicine. Vaszar LT; Cho MK; Raffin TA Pharmacogenomics; 2003 Mar; 4(2):107-12. PubMed ID: 12605543 [TBL] [Abstract][Full Text] [Related]
29. Personalized Medicine in the Paediatric Population: The Balance Between Pharmacogenetic Progress and Bioethics. Schiavone S; Neri M; Pomara C; Riezzo I; Trabace L; Turillazzi E Curr Pharm Biotechnol; 2017; 18(3):253-262. PubMed ID: 28176639 [TBL] [Abstract][Full Text] [Related]
30. The ethical implications of stratifying by race in pharmacogenomics. Lee SS Clin Pharmacol Ther; 2007 Jan; 81(1):122-5. PubMed ID: 17186010 [TBL] [Abstract][Full Text] [Related]
31. Ethical, social and legal implications of pharmacogenomics: a critical review. Moldrup C Community Genet; 2001; 4(4):204-14. PubMed ID: 12751484 [TBL] [Abstract][Full Text] [Related]
34. Ethical perspectives on pharmacogenomic profiling in the drug development process. Issa AM Nat Rev Drug Discov; 2002 Apr; 1(4):300-8. PubMed ID: 12120281 [TBL] [Abstract][Full Text] [Related]
35. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada. Bashir NS; Ungar WJ Genome; 2015 Dec; 58(12):527-40. PubMed ID: 26623513 [TBL] [Abstract][Full Text] [Related]
36. Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Smart A; Martin P; Parker M Bioethics; 2004 Aug; 18(4):322-42. PubMed ID: 15449405 [TBL] [Abstract][Full Text] [Related]
37. Protecting communities in pharmacogenetic and pharmacogenomic research. Weijer C; Miller PB Pharmacogenomics J; 2004; 4(1):9-16. PubMed ID: 14647406 [TBL] [Abstract][Full Text] [Related]
38. American Society of Clinical Oncology policy statement: oversight of clinical research. American Society of Clinical Oncology J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281 [TBL] [Abstract][Full Text] [Related]